- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Loop Diuretics Not Equally Effective Against Heart Failure
Yale researchers champion torsemide (Apr. 1)
Loop diuretics are the most widely prescribed heart failure medications, but few studies had extensively compared their effectiveness until Yale School of Medicine researchers examined three approved loop diuretics. They found that even though one of the drugs might offer more benefit, it is rarely prescribed.
Published in the April 1 early edition of the Journal of the American College of Cardiology, the research compared the potential benefits of using one of three loop diuretics: torsemide, furosemide, and bumetanide.
“Loop diuretics are a cornerstone of heart failure treatment, so it is vital to understand the comparative effectiveness and real-world use of the drugs within this class,” said lead author Dr. Behnood Bikdeli.
With more than 5 million Americans affected by heart failure, Bikdeli said that improving existing treatment options is key to providing the best care.
The researchers found that, among 274,515 hospitalizations for heart failure in the U.S. during 2009 and 2010, 92% of patients received loop diuretics during their hospital stay. Of those patients, 87% received furosemide as their only loop diuretic; 3% received bumetanide; and only 0.4% received torsemide, while 10% received a combination of these agents.
Although torsemide is slightly more expensive, the few available studies suggest that it lasts longer, is better tolerated, and might be associated with better clinical outcomes compared with the other two available loop diuretics, the authors say.
“There appears to be potential benefits from using torsemide compared with furosemide, but it is rarely used in practice,” Bikdeli remarked. “Furosemide is the dominantly used loop diuretic in practice; however, if the potential advantages of torsemide over furosemide are proven in subsequent comparative-effectiveness studies, this drug might become the preferred treatment of chronic heart failure.”
Source: Yale University; April 1, 2013.